Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study
This real-world study demonstrated numerically higher response rates and broadly similar rates of adverse events in this population compared with the MajesTEC-1 trial, despite many patients having higher disease burden and worse performance status. These findings from primarily community oncology settings suggest that teclistamab is an effective treatment option for patients with RRMM in the real world.
Authors
- Wenze Tang (ORCID: https://orcid.org/0000-0002-0491-8842)
- Tonya Le Blanc
- Bruce Feinberg
- Sarah Lucht (ORCID: https://orcid.org/0000-0001-5904-2844)
- Nina Kim (ORCID: https://orcid.org/0000-0002-1809-0417)
- Gilbert Ko
- Madison Brown
- Emily Bland
- Niodita Gupta-Werner
- Sarah Giegerich
- Moshe Levy
- Jason C. Fowler
- Shuchita Kaila
- JaLyna Laney
- Camryn Craig
- Binod Dhakal
- Jinghua He
- Peter Voorhees
Institutions
- Johnson & Johnson (United States) (US)
- Medical College of Wisconsin (US)
- Levine Cancer Institute (US)
- Cardinal Health (United States) (US)
- Baylor Scott & White Health (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1007/s40487-026-00429-8
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00